Cargando…

Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy.

Endogenously synthesised protoporphyrin IX (PpIX) following the administration of 5-amino-laevulinic acid (ALA) is an effective photosensitiser for photodynamic therapy (PDT). Following intravenous administration, PpIX accumulates predominantly in mucosa of hollow viscera and on light exposure, muco...

Descripción completa

Detalles Bibliográficos
Autores principales: Loh, C. S., MacRobert, A. J., Bedwell, J., Regula, J., Krasner, N., Bown, S. G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968297/
https://www.ncbi.nlm.nih.gov/pubmed/8318419
_version_ 1782134709753479168
author Loh, C. S.
MacRobert, A. J.
Bedwell, J.
Regula, J.
Krasner, N.
Bown, S. G.
author_facet Loh, C. S.
MacRobert, A. J.
Bedwell, J.
Regula, J.
Krasner, N.
Bown, S. G.
author_sort Loh, C. S.
collection PubMed
description Endogenously synthesised protoporphyrin IX (PpIX) following the administration of 5-amino-laevulinic acid (ALA) is an effective photosensitiser for photodynamic therapy (PDT). Following intravenous administration, PpIX accumulates predominantly in mucosa of hollow viscera and on light exposure, mucosal ablation results with relative sparing of the submucosa and muscularis layers. Oral administration is effective with ALA in contrast to conventional exogenous photosensitisers such as haematoporphyrin derivative and phthalocyanines. Oral administration of ALA is also simpler, safer, cheaper and more acceptable to patients. We studied the porphyrin sensitisation kinetics profile in the stomach, colon and bladder in normal rats following enterally and parenterally administered ALA using microscopic fluorescence photometric studies of frozen tissue sections. Mucosal cells in all three organs exhibit higher fluorescence levels as compared with underlying smooth muscle following both intravenous and oral administration. Peak concentration were seen 4 h after sensitisation at the highest doses used (200 mg kg-1 i.v., 400 mg kg-1 oral), and slightly earlier with lower doses. The temporal kinetics of both routes of administration were similar although a higher oral dose was required to achieve the same tissue concentration of PpIX. The highest level of fluorescence was achieved in the gastric mucosa and in decreasing levels, colonic and bladder mucosa. A similar degree of mucosal selectivity was achieved in each organ with each route of administration but an oral dose in excess of 40 mg kg-1 was required to achieve measurable PpIX sensitisation. In a pilot clinical study, two patients with inoperable rectal adenocarcinomas were given 30 mg kg-1 and one patient with sigmoid colon carcinoma was given 60 mg kg-1 ALA orally. Serial biopsies of normal and tumour areas were taken over the subsequent 24 h. Fluorescence microscopy of these specimens showed maximum accumulation of PpIX 4 to 6 h after administration of 30 mg kg-1 ALA. There was greater PpIX accumulation in tumour than adjacent normal mucosa in two patients. Preferential PpIX accumulation in tumour was greater in the patient receiving 60 mg kg-1 ALA. IMAGES:
format Text
id pubmed-1968297
institution National Center for Biotechnology Information
language English
publishDate 1993
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19682972009-09-10 Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy. Loh, C. S. MacRobert, A. J. Bedwell, J. Regula, J. Krasner, N. Bown, S. G. Br J Cancer Research Article Endogenously synthesised protoporphyrin IX (PpIX) following the administration of 5-amino-laevulinic acid (ALA) is an effective photosensitiser for photodynamic therapy (PDT). Following intravenous administration, PpIX accumulates predominantly in mucosa of hollow viscera and on light exposure, mucosal ablation results with relative sparing of the submucosa and muscularis layers. Oral administration is effective with ALA in contrast to conventional exogenous photosensitisers such as haematoporphyrin derivative and phthalocyanines. Oral administration of ALA is also simpler, safer, cheaper and more acceptable to patients. We studied the porphyrin sensitisation kinetics profile in the stomach, colon and bladder in normal rats following enterally and parenterally administered ALA using microscopic fluorescence photometric studies of frozen tissue sections. Mucosal cells in all three organs exhibit higher fluorescence levels as compared with underlying smooth muscle following both intravenous and oral administration. Peak concentration were seen 4 h after sensitisation at the highest doses used (200 mg kg-1 i.v., 400 mg kg-1 oral), and slightly earlier with lower doses. The temporal kinetics of both routes of administration were similar although a higher oral dose was required to achieve the same tissue concentration of PpIX. The highest level of fluorescence was achieved in the gastric mucosa and in decreasing levels, colonic and bladder mucosa. A similar degree of mucosal selectivity was achieved in each organ with each route of administration but an oral dose in excess of 40 mg kg-1 was required to achieve measurable PpIX sensitisation. In a pilot clinical study, two patients with inoperable rectal adenocarcinomas were given 30 mg kg-1 and one patient with sigmoid colon carcinoma was given 60 mg kg-1 ALA orally. Serial biopsies of normal and tumour areas were taken over the subsequent 24 h. Fluorescence microscopy of these specimens showed maximum accumulation of PpIX 4 to 6 h after administration of 30 mg kg-1 ALA. There was greater PpIX accumulation in tumour than adjacent normal mucosa in two patients. Preferential PpIX accumulation in tumour was greater in the patient receiving 60 mg kg-1 ALA. IMAGES: Nature Publishing Group 1993-07 /pmc/articles/PMC1968297/ /pubmed/8318419 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Loh, C. S.
MacRobert, A. J.
Bedwell, J.
Regula, J.
Krasner, N.
Bown, S. G.
Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy.
title Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy.
title_full Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy.
title_fullStr Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy.
title_full_unstemmed Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy.
title_short Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy.
title_sort oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968297/
https://www.ncbi.nlm.nih.gov/pubmed/8318419
work_keys_str_mv AT lohcs oralversusintravenousadministrationof5aminolaevulinicacidforphotodynamictherapy
AT macrobertaj oralversusintravenousadministrationof5aminolaevulinicacidforphotodynamictherapy
AT bedwellj oralversusintravenousadministrationof5aminolaevulinicacidforphotodynamictherapy
AT regulaj oralversusintravenousadministrationof5aminolaevulinicacidforphotodynamictherapy
AT krasnern oralversusintravenousadministrationof5aminolaevulinicacidforphotodynamictherapy
AT bownsg oralversusintravenousadministrationof5aminolaevulinicacidforphotodynamictherapy